# Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

> **NCT00335140** · PHASE2 · TERMINATED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 26 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** Rituximab
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **DRUG:** Leucovorin
- **DRUG:** Methotrexate
- **DRUG:** Procarbazine
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT00335140
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-08-23
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00335140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00335140, "Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00335140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*